CASE REPORT
Myositis in the course of the systemic form juvenile idiopathic arthritis
Submission date: 2013-11-18
Final revision date: 2014-03-10
Acceptance date: 2014-03-24
Online publication date: 2014-06-04
Publication date: 2014-04-30
Reumatologia 2014;52(2):142-145
KEYWORDS
TOPICS
ABSTRACT
The systemic juvenile idiopathic arthritis (SJIA) represents approximately 10% of all cases of JIA, there is no difference in onset rate between boys and girls. SJIA is characterized by pain of the joints, high, remitting fever, polymorphous skin rash and symptoms in other organs.
Hepatosplenomegaly, lymphadenopathy, serositis, features of acute inflammation are observed. Often there is pain of the joints. But myositis is observed rarely. The presented case is 22-years-old male suffering from the systemic JIA, with fevers and myositis symptoms (mainly intercostal muscles) dominating in the initial stage of the disease. Discussed was the clinical image, diagnostic issues and treatment.
Hepatosplenomegaly, lymphadenopathy, serositis, features of acute inflammation are observed. Often there is pain of the joints. But myositis is observed rarely. The presented case is 22-years-old male suffering from the systemic JIA, with fevers and myositis symptoms (mainly intercostal muscles) dominating in the initial stage of the disease. Discussed was the clinical image, diagnostic issues and treatment.
REFERENCES (17)
1.
Woo P. Systemic juvenile rheumatoid arthritis: diagnosis, management, and outcome. Nature Clinical Practice: Rheumatology 2006; 2: 28-34. .
2.
De Benedetti F. Inflammatory cytokines in the pathogenesis and treatment of systemic juvenile idiopathic arthritis – Basic science for the clinician. Pediatric Rheumatology Online Journal 2005; 3: 122-136. .
3.
Cassidy JT, et al. Juvenile rheumatoid arthritis. In: Textbook of Pediatric Rheumatology, Cassidy JT, Petty RE, eds. W. B. Saunders Co., Philadelphia 2001; 218-322. .
4.
Vastert SJ, Kuis W, Grom AA. Systemic JIA: New developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009; 23:655-664. .
5.
Lindehammar H, Lindvall B. Muscle involvement in juvenile idiopathic arthritis. Rheumatology 2004; 43: 1546-1554. .
6.
Rosenbaum R. Neuromuscular complications of connective tissue diseases. Muscle Nerve 2001; 24: 154-169. .
7.
Hedengren E, Knutson LM, Haglund-Akerlind Y, Hagelberg S. Lower extremity isometric joint torque in children with juvenile chronic arthritis. Scand J Rheumatol 2001; 30: 69-76. .
8.
Lindehammar H, Backman E. Muscle function in juvenile chronic arthritis. J Rheumatol 1995; 22: 1159-1165. .
9.
Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255-286. .
10.
Gietka P, Wieteska-Klimczak A, Smorczewska-Kiljan A i wsp. Reaktywne zespoły hemofagocytarne u dzieci z chorobami reumatycznymi. Reumatologia 2011; 49: 96-107. .
11.
Gietka P. Macropahage activation syndrome – szczególna postać wtórnego zespołu hemofagocytarnego u dzieci z układowymi zapalnymi chorobami tkanki łącznej. Lekarz 2005; 9: 103-109. .
12.
Cimaz R, Van Scheven A, Hofer M. Systemic-onset juvenile idiopathic arthritis: the changing life of a rare disease. Swiss Med Wkly 2012; 142: w13582. .
13.
Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 545-555. .
14.
Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011; 63: 465-482. .
15.
Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012; 64: 557-567 .
16.
Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-2406. .
17.
Cimaz R, Cazalis MA, Gerloni V, et al. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 2007; 66: 900-904.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
